Industry Satellite Symposia webcasts

20 Mar 2024

Novocure GmbH
Tumor treating fields therapy: A force for change in lung cancer  

Watch session

• Welcome and introduction
  Maurice Perol, France
• The scientific basis of TTFields
  Rami El Shafie, Germany
• The clinical evidence behind TTFields therapy in NSCLC
  Rupesh Kotecha, United States of America
• The future of TTFields therapy in NSCLC
  Giovanni Luca Ceresoli, Italy
• Closing remarks
  Maurice Perol

Clinical Care Options, LLC
TROP-2–targeted ADCs for NSCLC: Integrating a new therapeutic option

Watch session

• Welcome and introduction
  David Planchard, France
• Role of TROP-2 in NSCLC
  David Planchard, France
• Latest therapeutic advancements in targeting TROP-2 in NSCLC
  Helena A. Yu, United States of America
• Contemplating the future role of targeting TROP-2 in NSCLC
  Luis Paz-Ares, Spain
• Panel discussion with audience question and answer session
  Helena A. Yu, United States of America

21 Mar 2024

Janssen Pharmaceutica NV
Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Watch session

• Welcome and introductions
  Martin Reck, Germany
• Guiding treatment decision choices: Molecular pathology in EGFR-mutant NSCLC
  Umberto Malapelle, Italy
• Navigating the current treatment landscape for common EGFR-mutant NSCLC
  Raffaele Califano, United Kingdom
• Advances in EGFR exon20ins mutations in NSCLC
  Pascale Tomasini, France
• Living with lung cancer: Implementing shared-decision making with our patients
  Martin Reck, Germany
• Closing remarks
  Umberto Malapelle, Italy

22 Mar 2024

Daiichi Sankyo
Targeting rare mutations in NSCLC: A focus on HER2m

Watch session

• Welcome and introduction
  Egbert Smit, Netherlands
• Small numbers, big impact: The importance of testing for rare mutations in mNSCLC
  Luka Brcic, Austria
• The evolving treatment landscape for rare mutations: Focus on HER2m
  Sonja Loges, Germany
• Safety considerations for ADCs
  Egbert Smit, Netherlands
• Audience Q&A and closing remarks
  Egbert Smit, Netherlands

Seagen
Moving forward in metastatic NSCLC: The role of ADCs

Watch session

• Welcome and introduction
  Martin Reck, Germany
• From the current status to unmet needs
  Martin Reck, Germany
• ADCs in late-stage development: Who can benefit?
  Enriqueta Felip, Spain
• Beyond the horizon: Unveiling novel ADC targets
  Anna Minchom, United Kingdom
• Closing remarks
  Martin Reck, Germany

Thermo Fisher Scientific
The critical role of timely genomic profiling in NSCLC

Watch session

• Welcome and introduction
  Fernando Lopez-Rios, Spain
• Navigating NSCLC: Oncologists' perspective on biomarker testing needs
  Francesco Passiglia, Italy
• When tissue is the issue: Optimising rapid liquid biopsy testing in NSCLC
  Fernando Lopez-Rios, Spain
• Insights from in-house: evaluating the impact of ultra-fast NGS on patient outcomes
  Morten Grauslund, Denmark
• Closing remarks
  Fernando Lopez-Rios, Spain